MediaAlpha has dropped 10% this week to $12.38 — a sharp reversal from the pre-earnings optimism captured in last week's notes, with the stock now trading below most of the freshly raised analyst targets.
The analyst response to the August 3 print tells an interesting story about conviction. RBC Capital's Ben Hendrix raised his target from $11 to $15 this morning, maintaining Outperform — a notably aggressive lift filed the day after the stock fell. That follows July 30 raises from Goldman Sachs (to $14, Neutral) and Canaccord Genuity (to $17, Buy). The consensus mean target holds at $14.83, roughly 20% above the current price. The direction of travel across the Street is uniformly higher — every recent action has been a raise, not a cut — which contrasts sharply with the stock's actual performance this week. That divergence between rising Street targets and a falling share price is the central tension right now.
The earnings reaction itself was muted in percentage terms but clearly disappointed some holders. The stock moved -1.8% on the day of the July 29 print, a modest reaction by historical standards. What has done more damage is the steady bleed since — down 10% on the week against a peer group that has largely held up or gained. PINS rose 5% on the week, gained 10%, and added nearly 2%. is the one peer tracking lower, off 12% on the week, suggesting some idiosyncratic pressure across insurance-adjacent digital names. is underperforming even that weakness.
The lending market offers no drama. Short interest is essentially flat on the week at 4.8% of the free float, and has fallen around 23% over the past month — the steady decline that was underway before earnings has continued. Borrow costs have halved over the past week to just 0.52%, and availability is extraordinarily loose at 1,581% — roughly 22 million shares available against just 2.7 million short. There is no short-side squeeze pressure here. The sell-off is coming from long holders, not fresh short builds. The ORTEX short score sits at 49, broadly neutral, unchanged over the past ten days.
Options positioning has shifted meaningfully since the pre-earnings notes. The put/call ratio has jumped to 0.016 — still low in absolute terms but now nearly three standard deviations above its 20-day average of 0.009. Before earnings, the elevated PCR deviation reflected a call-buying surge. Post-print, the same statistical deviation now reflects a relative pickup in put activity. It remains a thin options market for this name, so small absolute moves register as large z-score swings, but the directional rotation from calls to puts is real.
Founder-level selling has continued. Eugene Nonko sold roughly 58,000 shares across July 27-29, at prices between $13.28 and $14.05 — all above the current $12.38. The 90-day net insider figure runs to over 440,000 shares sold. Nonko's reported holding has dropped to 1.33 million shares (2.5% of the company), down from prior filings. White Mountains Insurance Group remains the dominant anchor holder at 33.7% of shares — that position has not changed.
The valuation setup looks increasingly interesting to the Street. The stock trades at 8.7x trailing earnings and 5.4x EV/EBITDA, with the P/B ratio easing to 1.96x over the past month. EPS surprise ranks at the 83rd percentile — the company has consistently beaten estimates — while forward EPS momentum scores remain weak at the 13th percentile on a 30-day basis. That combination of a stock beating near-term estimates while forward expectations drift lower captures the structural tension in the bull-bear debate: P&C vertical strength is real, but Health segment weakness and cautious forward guidance are keeping a ceiling on re-rating.
The next earnings event is October 30. Between now and then, the key variable to track is whether the insider selling pace continues into sub-$13 territory — or stops — and whether the Street's unanimous target-raising cycle translates into any actual buying interest at these levels.
See the live data behind this article on ORTEX.
Open MAX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
